NCT06448208Active, not recruiting
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Definition of PET REsponSe CrItEria for Neuroendocrine Tumors (PRESCIENT)
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 11 (actual)
- First submitted
- 3 Jun 2024
- Start date
- 3 Jun 2024
- Primary completion date
- Jun 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06448208
What you commit to
- Study type: Observational
- Participants enrolled: 11
- From 3 Jun 2024 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Neuroendocrine Carcinoma), small and large cell type; MIxed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN).
- Presence of somatostatin receptor negative lesions.
Who the study is looking for
- Histologically proven or cytologically confirmed, metastatic or inoperable NETs
- Measurable disease as defined by RECIST 1.1.
- Overexpression of somatostatin receptors of the target lesions at somatostatin receptor imaging (68Ga-DOTATATE or 64Cu-DOTATATE PET/CT) with SUV of lesions greater than normal liver at least in 1 metastasis.
Criteria the registry did not label
- Subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated G1, G2 or G3 neuroendocrine tumors (NETs) candidate to receive PRRT with 177Lu-DOTATATE per standard of care.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.